載入...
Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
The role of the epidermal growth factor receptor (EGFR) mutation status testing in lung squamous cell carcinoma (SqCC) remains controversial. Evidence of the effectiveness of osimertinib in SqCC with EGFR T790M mutation is limited. Here, we describe a hitherto unreported case of a stage III SqCC pat...
Na minha lista:
| 發表在: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons Australia, Ltd
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7471018/ https://ncbi.nlm.nih.gov/pubmed/32667739 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13431 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|